Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study

The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mikrobiyoloji bülteni 2011-04, Vol.45 (2), p.197-209
Hauptverfasser: Korten, Volkan, Söyletir, Güner, Yalçın, Ata Nevzat, Oğünç, Dilara, Dokuzoğuz, Başak, Esener, Harika, Ulusoy, Sercan, Tünger, Alper, Aygen, Bilgehan, Sümerkan, Bülent, Arman, Dilek, Dizbay, Murat, Akova, Murat, Hasçelik, Gülşen, Eraksoy, Haluk, Başaran, Seniha, Köksal, Iftihar, Bayramoğlu, Gülçin, Akalın, Halis, Sınırtaş, Melda
Format: Artikel
Sprache:tur
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 209
container_issue 2
container_start_page 197
container_title Mikrobiyoloji bülteni
container_volume 45
creator Korten, Volkan
Söyletir, Güner
Yalçın, Ata Nevzat
Oğünç, Dilara
Dokuzoğuz, Başak
Esener, Harika
Ulusoy, Sercan
Tünger, Alper
Aygen, Bilgehan
Sümerkan, Bülent
Arman, Dilek
Dizbay, Murat
Akova, Murat
Hasçelik, Gülşen
Eraksoy, Haluk
Başaran, Seniha
Köksal, Iftihar
Bayramoğlu, Gülçin
Akalın, Halis
Sınırtaş, Melda
description The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008. The origin of the isolates was patients with nosocomial pneumonia (42.4%), bloodstream infections (%40.4), and complicated intraabdominal infections (17.1%). Of the isolates, 51.8% were obtained from ICU patients. The study isolates consisted of Pseudomonas spp. in 49.8%, Enterobacteriaceae in 40.3%, and other gram-negative agents in 9.9%. The minimum inhibitory concentrations (MIC) for doripenem, imipenem and meropenem were determined for all isolates in each center using Etest® strips (AB Biodisk, Solna, Sweden). Of the isolates, 188 (31.5%) were resistant to at least one of the carbapenems. MIC50 of doripenem against Pseudomonas spp. Was 1 mg/L which was similar to that of meropenem and two-fold lower than imipenem. Susceptibility to carbapenems in P.aeruginosa was 64% for doripenem at an MIC level of 2 mg/L, 53.9% and 63% for imipenem and meropenem at an MIC level of 4 mg/L, respectively. Doripenem and meropenem showed similar activity with the MIC90 of 0.12 mg/L whereas imipenem was four-fold less active at 0.5 mg/L. Against other gramnegative pathogens, mostly Acinetobacter spp., MIC50 was 8 mg/L for doripenem and 32 mg/L for other two carbapenems. P.aeruginosa isolates were inhibited 84.2% with doripenem and 72.1% with meropenem at the MIC level of 8 mg/L. Doripenem generally showed similar or slightly better activity than meropenem and better activity than imipenem against pathogens collected in this study. Against Pseudomonas spp., doripenem was the most active of the three carbapenems. Doripenem and meropenem were equally active against Enterobacteriaceae and at least four-fold more active than imipenem. It was concluded that doripenem seemed to be a promising agent in the treatment of nosocomial pneumonia, blood stream infections and intraabdominal infections particularly in patients who were under risk of developing antimicrobial resistance.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_872435132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>872435132</sourcerecordid><originalsourceid>FETCH-LOGICAL-p553-398328d884ad97cb1ed8678c02a2335d7e0057cb18caf7e445d66ab4338b6aee3</originalsourceid><addsrcrecordid>eNo1kM1ugzAQhH1o1URpXqHyrSckgw2Y3iLUPylVeuCOFrwhbsGmtokU9eVLlHQvu5qZ_Q5zQ5aM5yIqWJEtyNr7LzaPKGJZsDuySOJMCJbxJfkt7TCCg6CPSPEI_TSf1lC7p9rQow7OUmhnVweN_iy34BoY0eDgKXSgjQ-0czBEBrsLZoRwsB0a_0SryX1rf6AKApyfy93H56asqA-TOt2T2z30HtfXvSLVy3NVvkXb3et7udlGY5ryiBeSJ1JJKUAVedvEqGSWy5YlkHCeqhwZS8-6bGGfoxCpyjJoBOeyyQCRr8jjBTs6-zOhD_WgfYt9Dwbt5GuZJ4KnMU_m5MM1OTUDqnp0egB3qv_r4n9Oh2fA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>872435132</pqid></control><display><type>article</type><title>Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study</title><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ)</source><creator>Korten, Volkan ; Söyletir, Güner ; Yalçın, Ata Nevzat ; Oğünç, Dilara ; Dokuzoğuz, Başak ; Esener, Harika ; Ulusoy, Sercan ; Tünger, Alper ; Aygen, Bilgehan ; Sümerkan, Bülent ; Arman, Dilek ; Dizbay, Murat ; Akova, Murat ; Hasçelik, Gülşen ; Eraksoy, Haluk ; Başaran, Seniha ; Köksal, Iftihar ; Bayramoğlu, Gülçin ; Akalın, Halis ; Sınırtaş, Melda</creator><creatorcontrib>Korten, Volkan ; Söyletir, Güner ; Yalçın, Ata Nevzat ; Oğünç, Dilara ; Dokuzoğuz, Başak ; Esener, Harika ; Ulusoy, Sercan ; Tünger, Alper ; Aygen, Bilgehan ; Sümerkan, Bülent ; Arman, Dilek ; Dizbay, Murat ; Akova, Murat ; Hasçelik, Gülşen ; Eraksoy, Haluk ; Başaran, Seniha ; Köksal, Iftihar ; Bayramoğlu, Gülçin ; Akalın, Halis ; Sınırtaş, Melda</creatorcontrib><description>The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008. The origin of the isolates was patients with nosocomial pneumonia (42.4%), bloodstream infections (%40.4), and complicated intraabdominal infections (17.1%). Of the isolates, 51.8% were obtained from ICU patients. The study isolates consisted of Pseudomonas spp. in 49.8%, Enterobacteriaceae in 40.3%, and other gram-negative agents in 9.9%. The minimum inhibitory concentrations (MIC) for doripenem, imipenem and meropenem were determined for all isolates in each center using Etest® strips (AB Biodisk, Solna, Sweden). Of the isolates, 188 (31.5%) were resistant to at least one of the carbapenems. MIC50 of doripenem against Pseudomonas spp. Was 1 mg/L which was similar to that of meropenem and two-fold lower than imipenem. Susceptibility to carbapenems in P.aeruginosa was 64% for doripenem at an MIC level of 2 mg/L, 53.9% and 63% for imipenem and meropenem at an MIC level of 4 mg/L, respectively. Doripenem and meropenem showed similar activity with the MIC90 of 0.12 mg/L whereas imipenem was four-fold less active at 0.5 mg/L. Against other gramnegative pathogens, mostly Acinetobacter spp., MIC50 was 8 mg/L for doripenem and 32 mg/L for other two carbapenems. P.aeruginosa isolates were inhibited 84.2% with doripenem and 72.1% with meropenem at the MIC level of 8 mg/L. Doripenem generally showed similar or slightly better activity than meropenem and better activity than imipenem against pathogens collected in this study. Against Pseudomonas spp., doripenem was the most active of the three carbapenems. Doripenem and meropenem were equally active against Enterobacteriaceae and at least four-fold more active than imipenem. It was concluded that doripenem seemed to be a promising agent in the treatment of nosocomial pneumonia, blood stream infections and intraabdominal infections particularly in patients who were under risk of developing antimicrobial resistance.</description><identifier>ISSN: 0374-9096</identifier><identifier>PMID: 21644063</identifier><language>tur</language><publisher>Turkey</publisher><subject>Anti-Bacterial Agents - pharmacology ; Bacteremia - microbiology ; Carbapenems - pharmacology ; Cross Infection - microbiology ; Drug Resistance, Bacterial ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacterial Infections - microbiology ; Humans ; Imipenem - pharmacology ; Intensive Care Units ; Microbial Sensitivity Tests ; Pneumonia, Bacterial - microbiology ; Thienamycins - pharmacology ; Turkey</subject><ispartof>Mikrobiyoloji bülteni, 2011-04, Vol.45 (2), p.197-209</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21644063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Korten, Volkan</creatorcontrib><creatorcontrib>Söyletir, Güner</creatorcontrib><creatorcontrib>Yalçın, Ata Nevzat</creatorcontrib><creatorcontrib>Oğünç, Dilara</creatorcontrib><creatorcontrib>Dokuzoğuz, Başak</creatorcontrib><creatorcontrib>Esener, Harika</creatorcontrib><creatorcontrib>Ulusoy, Sercan</creatorcontrib><creatorcontrib>Tünger, Alper</creatorcontrib><creatorcontrib>Aygen, Bilgehan</creatorcontrib><creatorcontrib>Sümerkan, Bülent</creatorcontrib><creatorcontrib>Arman, Dilek</creatorcontrib><creatorcontrib>Dizbay, Murat</creatorcontrib><creatorcontrib>Akova, Murat</creatorcontrib><creatorcontrib>Hasçelik, Gülşen</creatorcontrib><creatorcontrib>Eraksoy, Haluk</creatorcontrib><creatorcontrib>Başaran, Seniha</creatorcontrib><creatorcontrib>Köksal, Iftihar</creatorcontrib><creatorcontrib>Bayramoğlu, Gülçin</creatorcontrib><creatorcontrib>Akalın, Halis</creatorcontrib><creatorcontrib>Sınırtaş, Melda</creatorcontrib><title>Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study</title><title>Mikrobiyoloji bülteni</title><addtitle>Mikrobiyol Bul</addtitle><description>The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008. The origin of the isolates was patients with nosocomial pneumonia (42.4%), bloodstream infections (%40.4), and complicated intraabdominal infections (17.1%). Of the isolates, 51.8% were obtained from ICU patients. The study isolates consisted of Pseudomonas spp. in 49.8%, Enterobacteriaceae in 40.3%, and other gram-negative agents in 9.9%. The minimum inhibitory concentrations (MIC) for doripenem, imipenem and meropenem were determined for all isolates in each center using Etest® strips (AB Biodisk, Solna, Sweden). Of the isolates, 188 (31.5%) were resistant to at least one of the carbapenems. MIC50 of doripenem against Pseudomonas spp. Was 1 mg/L which was similar to that of meropenem and two-fold lower than imipenem. Susceptibility to carbapenems in P.aeruginosa was 64% for doripenem at an MIC level of 2 mg/L, 53.9% and 63% for imipenem and meropenem at an MIC level of 4 mg/L, respectively. Doripenem and meropenem showed similar activity with the MIC90 of 0.12 mg/L whereas imipenem was four-fold less active at 0.5 mg/L. Against other gramnegative pathogens, mostly Acinetobacter spp., MIC50 was 8 mg/L for doripenem and 32 mg/L for other two carbapenems. P.aeruginosa isolates were inhibited 84.2% with doripenem and 72.1% with meropenem at the MIC level of 8 mg/L. Doripenem generally showed similar or slightly better activity than meropenem and better activity than imipenem against pathogens collected in this study. Against Pseudomonas spp., doripenem was the most active of the three carbapenems. Doripenem and meropenem were equally active against Enterobacteriaceae and at least four-fold more active than imipenem. It was concluded that doripenem seemed to be a promising agent in the treatment of nosocomial pneumonia, blood stream infections and intraabdominal infections particularly in patients who were under risk of developing antimicrobial resistance.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Bacteremia - microbiology</subject><subject>Carbapenems - pharmacology</subject><subject>Cross Infection - microbiology</subject><subject>Drug Resistance, Bacterial</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacterial Infections - microbiology</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Intensive Care Units</subject><subject>Microbial Sensitivity Tests</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Thienamycins - pharmacology</subject><subject>Turkey</subject><issn>0374-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kM1ugzAQhH1o1URpXqHyrSckgw2Y3iLUPylVeuCOFrwhbsGmtokU9eVLlHQvu5qZ_Q5zQ5aM5yIqWJEtyNr7LzaPKGJZsDuySOJMCJbxJfkt7TCCg6CPSPEI_TSf1lC7p9rQow7OUmhnVweN_iy34BoY0eDgKXSgjQ-0czBEBrsLZoRwsB0a_0SryX1rf6AKApyfy93H56asqA-TOt2T2z30HtfXvSLVy3NVvkXb3et7udlGY5ryiBeSJ1JJKUAVedvEqGSWy5YlkHCeqhwZS8-6bGGfoxCpyjJoBOeyyQCRr8jjBTs6-zOhD_WgfYt9Dwbt5GuZJ4KnMU_m5MM1OTUDqnp0egB3qv_r4n9Oh2fA</recordid><startdate>201104</startdate><enddate>201104</enddate><creator>Korten, Volkan</creator><creator>Söyletir, Güner</creator><creator>Yalçın, Ata Nevzat</creator><creator>Oğünç, Dilara</creator><creator>Dokuzoğuz, Başak</creator><creator>Esener, Harika</creator><creator>Ulusoy, Sercan</creator><creator>Tünger, Alper</creator><creator>Aygen, Bilgehan</creator><creator>Sümerkan, Bülent</creator><creator>Arman, Dilek</creator><creator>Dizbay, Murat</creator><creator>Akova, Murat</creator><creator>Hasçelik, Gülşen</creator><creator>Eraksoy, Haluk</creator><creator>Başaran, Seniha</creator><creator>Köksal, Iftihar</creator><creator>Bayramoğlu, Gülçin</creator><creator>Akalın, Halis</creator><creator>Sınırtaş, Melda</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201104</creationdate><title>Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study</title><author>Korten, Volkan ; Söyletir, Güner ; Yalçın, Ata Nevzat ; Oğünç, Dilara ; Dokuzoğuz, Başak ; Esener, Harika ; Ulusoy, Sercan ; Tünger, Alper ; Aygen, Bilgehan ; Sümerkan, Bülent ; Arman, Dilek ; Dizbay, Murat ; Akova, Murat ; Hasçelik, Gülşen ; Eraksoy, Haluk ; Başaran, Seniha ; Köksal, Iftihar ; Bayramoğlu, Gülçin ; Akalın, Halis ; Sınırtaş, Melda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p553-398328d884ad97cb1ed8678c02a2335d7e0057cb18caf7e445d66ab4338b6aee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>tur</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Bacteremia - microbiology</topic><topic>Carbapenems - pharmacology</topic><topic>Cross Infection - microbiology</topic><topic>Drug Resistance, Bacterial</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacterial Infections - microbiology</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Intensive Care Units</topic><topic>Microbial Sensitivity Tests</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Thienamycins - pharmacology</topic><topic>Turkey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Korten, Volkan</creatorcontrib><creatorcontrib>Söyletir, Güner</creatorcontrib><creatorcontrib>Yalçın, Ata Nevzat</creatorcontrib><creatorcontrib>Oğünç, Dilara</creatorcontrib><creatorcontrib>Dokuzoğuz, Başak</creatorcontrib><creatorcontrib>Esener, Harika</creatorcontrib><creatorcontrib>Ulusoy, Sercan</creatorcontrib><creatorcontrib>Tünger, Alper</creatorcontrib><creatorcontrib>Aygen, Bilgehan</creatorcontrib><creatorcontrib>Sümerkan, Bülent</creatorcontrib><creatorcontrib>Arman, Dilek</creatorcontrib><creatorcontrib>Dizbay, Murat</creatorcontrib><creatorcontrib>Akova, Murat</creatorcontrib><creatorcontrib>Hasçelik, Gülşen</creatorcontrib><creatorcontrib>Eraksoy, Haluk</creatorcontrib><creatorcontrib>Başaran, Seniha</creatorcontrib><creatorcontrib>Köksal, Iftihar</creatorcontrib><creatorcontrib>Bayramoğlu, Gülçin</creatorcontrib><creatorcontrib>Akalın, Halis</creatorcontrib><creatorcontrib>Sınırtaş, Melda</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Mikrobiyoloji bülteni</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Korten, Volkan</au><au>Söyletir, Güner</au><au>Yalçın, Ata Nevzat</au><au>Oğünç, Dilara</au><au>Dokuzoğuz, Başak</au><au>Esener, Harika</au><au>Ulusoy, Sercan</au><au>Tünger, Alper</au><au>Aygen, Bilgehan</au><au>Sümerkan, Bülent</au><au>Arman, Dilek</au><au>Dizbay, Murat</au><au>Akova, Murat</au><au>Hasçelik, Gülşen</au><au>Eraksoy, Haluk</au><au>Başaran, Seniha</au><au>Köksal, Iftihar</au><au>Bayramoğlu, Gülçin</au><au>Akalın, Halis</au><au>Sınırtaş, Melda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study</atitle><jtitle>Mikrobiyoloji bülteni</jtitle><addtitle>Mikrobiyol Bul</addtitle><date>2011-04</date><risdate>2011</risdate><volume>45</volume><issue>2</issue><spage>197</spage><epage>209</epage><pages>197-209</pages><issn>0374-9096</issn><abstract>The aim of this study was to determine the in vitro activities of doripenem, imipenem, and meropenem against clinical gram-negative isolates. A total of 596 clinical isolates were obtained from intensive care unit (ICU) and non-ICU patients in 10 centers over Turkey between September-December 2008. The origin of the isolates was patients with nosocomial pneumonia (42.4%), bloodstream infections (%40.4), and complicated intraabdominal infections (17.1%). Of the isolates, 51.8% were obtained from ICU patients. The study isolates consisted of Pseudomonas spp. in 49.8%, Enterobacteriaceae in 40.3%, and other gram-negative agents in 9.9%. The minimum inhibitory concentrations (MIC) for doripenem, imipenem and meropenem were determined for all isolates in each center using Etest® strips (AB Biodisk, Solna, Sweden). Of the isolates, 188 (31.5%) were resistant to at least one of the carbapenems. MIC50 of doripenem against Pseudomonas spp. Was 1 mg/L which was similar to that of meropenem and two-fold lower than imipenem. Susceptibility to carbapenems in P.aeruginosa was 64% for doripenem at an MIC level of 2 mg/L, 53.9% and 63% for imipenem and meropenem at an MIC level of 4 mg/L, respectively. Doripenem and meropenem showed similar activity with the MIC90 of 0.12 mg/L whereas imipenem was four-fold less active at 0.5 mg/L. Against other gramnegative pathogens, mostly Acinetobacter spp., MIC50 was 8 mg/L for doripenem and 32 mg/L for other two carbapenems. P.aeruginosa isolates were inhibited 84.2% with doripenem and 72.1% with meropenem at the MIC level of 8 mg/L. Doripenem generally showed similar or slightly better activity than meropenem and better activity than imipenem against pathogens collected in this study. Against Pseudomonas spp., doripenem was the most active of the three carbapenems. Doripenem and meropenem were equally active against Enterobacteriaceae and at least four-fold more active than imipenem. It was concluded that doripenem seemed to be a promising agent in the treatment of nosocomial pneumonia, blood stream infections and intraabdominal infections particularly in patients who were under risk of developing antimicrobial resistance.</abstract><cop>Turkey</cop><pmid>21644063</pmid><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0374-9096
ispartof Mikrobiyoloji bülteni, 2011-04, Vol.45 (2), p.197-209
issn 0374-9096
language tur
recordid cdi_proquest_miscellaneous_872435132
source MEDLINE; Free E-Journal (出版社公開部分のみ)
subjects Anti-Bacterial Agents - pharmacology
Bacteremia - microbiology
Carbapenems - pharmacology
Cross Infection - microbiology
Drug Resistance, Bacterial
Gram-Negative Bacteria - drug effects
Gram-Negative Bacterial Infections - microbiology
Humans
Imipenem - pharmacology
Intensive Care Units
Microbial Sensitivity Tests
Pneumonia, Bacterial - microbiology
Thienamycins - pharmacology
Turkey
title Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T05%3A23%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20evaluation%20of%20in%20vitro%20activities%20of%20carbapenems%20against%20gram-negative%20pathogens:%20Turkish%20data%20of%20COMPACT%20study&rft.jtitle=Mikrobiyoloji%20b%C3%BClteni&rft.au=Korten,%20Volkan&rft.date=2011-04&rft.volume=45&rft.issue=2&rft.spage=197&rft.epage=209&rft.pages=197-209&rft.issn=0374-9096&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E872435132%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=872435132&rft_id=info:pmid/21644063&rfr_iscdi=true